DE69636278D1 - Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper - Google Patents
Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörperInfo
- Publication number
- DE69636278D1 DE69636278D1 DE69636278T DE69636278T DE69636278D1 DE 69636278 D1 DE69636278 D1 DE 69636278D1 DE 69636278 T DE69636278 T DE 69636278T DE 69636278 T DE69636278 T DE 69636278T DE 69636278 D1 DE69636278 D1 DE 69636278D1
- Authority
- DE
- Germany
- Prior art keywords
- muscle protein
- antibodies
- inhibitor
- antibody
- receptor antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4658795 | 1995-02-13 | ||
JP4658795 | 1995-02-13 | ||
JP33435695 | 1995-11-30 | ||
JP33435695 | 1995-11-30 | ||
PCT/JP1996/000310 WO1996025174A1 (fr) | 1995-02-13 | 1996-02-13 | Inhibiteur de decomposition des proteines musculaires contenant un anticorps du recepteur de l'interleukine-6 |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69636278D1 true DE69636278D1 (de) | 2006-08-03 |
DE69636278T2 DE69636278T2 (de) | 2007-05-03 |
Family
ID=26386686
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69636278T Expired - Lifetime DE69636278T2 (de) | 1995-02-13 | 1996-02-13 | Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper |
Country Status (11)
Country | Link |
---|---|
US (1) | US6261560B1 (de) |
EP (1) | EP0811384B1 (de) |
JP (1) | JP4540132B2 (de) |
AT (1) | ATE330629T1 (de) |
AU (1) | AU693318B2 (de) |
CA (1) | CA2211578C (de) |
DE (1) | DE69636278T2 (de) |
DK (1) | DK0811384T3 (de) |
ES (1) | ES2264135T3 (de) |
PT (1) | PT811384E (de) |
WO (1) | WO1996025174A1 (de) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2147442C1 (ru) * | 1994-10-21 | 2000-04-20 | Кисимото Тадамицу | Фармацевтическая композиция для профилактики или лечения заболеваний, вызываемых образованием il-6 |
ATE547119T1 (de) | 1997-03-21 | 2012-03-15 | Chugai Pharmaceutical Co Ltd | Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen |
AU747883B2 (en) * | 1997-08-15 | 2002-05-30 | Chugai Seiyaku Kabushiki Kaisha | Preventives and/or remedies for systemic lupus erythematosus containing anti-IL-6 receptor antibody as the active ingredient |
US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
DE69937994T2 (de) | 1998-03-17 | 2008-12-24 | Chugai Seiyaku K.K. | Prophylaktische oder therapeutische mittel gegen entzündliche erkrankungen des verdauungstraktes enthaltend antagonistische il-6 rezeptor antikörper |
EP1001028B1 (de) | 1998-04-17 | 2006-05-31 | Suntory Limited | Gen, das für ein protein mit auron-synthetisierender aktivität kodiert. |
DE60133029T2 (de) | 2000-10-25 | 2009-03-12 | Chugai Seiyaku K.K. | Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff |
EP1347300B1 (de) * | 2000-11-30 | 2007-04-18 | Chugai Seiyaku Kabushiki Kaisha | Messverfahren für die bindungsaktivität eines liganden bindenden proteins mit geringer chemischer stabilität für den ersten liganden |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
KR20100120246A (ko) * | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | 항 il-6 항체, 조성물, 방법 및 용도 |
EP3578168A1 (de) | 2002-02-14 | 2019-12-11 | Chugai Seiyaku Kabushiki Kaisha | Formulierung von antikörperhaltigen lösungen mit einem zucker als stabilisator |
KR101142624B1 (ko) * | 2003-02-24 | 2012-06-15 | 추가이 세이야쿠 가부시키가이샤 | 인터루킨-6 길항제를 함유하는 척수손상 치료제 |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US20050100550A1 (en) * | 2003-11-10 | 2005-05-12 | Mohit Trikha | Anti-angiogenic uses of IL-6 antagonists |
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
JPWO2005090405A1 (ja) | 2004-03-24 | 2008-04-17 | 中外製薬株式会社 | インターロイキン−6受容体に対するヒト型化抗体のサブタイプ |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
EP1941907B1 (de) * | 2005-10-14 | 2016-03-23 | Fukuoka University | Mittel zur unterdrückung von transplantations-inselzell-dysfunktion bei inselzelltransplantationen |
KR101239051B1 (ko) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | 심장질환 치료제 |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
CN101370521A (zh) | 2006-01-27 | 2009-02-18 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
CA2648644C (en) * | 2006-04-07 | 2016-01-05 | Osaka University | Muscle regeneration promoter |
US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
EP2057191A1 (de) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Gegen il-6r gerichtete aminosäuresequenzen und polypeptide, die diese enthalten, zur behandlung von mit der durch il-6 vermittelten signalübertragung assoziierten krankheiten und erkrankungen |
CN101646459B (zh) | 2007-01-23 | 2014-02-12 | 国立大学法人信州大学 | 慢性排斥反应抑制剂 |
AU2008254578B2 (en) * | 2007-05-21 | 2013-06-06 | Alderbio Holdings Llc | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
NZ597767A (en) | 2007-05-21 | 2013-06-28 | Bristol Myers Squibb Co | Antibodies to IL-6 and use thereof |
US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
US7906117B2 (en) * | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
PE20091174A1 (es) * | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
WO2009148148A1 (ja) | 2008-06-05 | 2009-12-10 | 国立がんセンター総長が代表する日本国 | 神経浸潤抑制剤 |
US8188235B2 (en) | 2008-06-18 | 2012-05-29 | Pfizer Inc. | Antibodies to IL-6 and their uses |
US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
US9452227B2 (en) * | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
EP2417162A2 (de) | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Verbesserte, gegen il-6r gerichtete amiinosäuresequenzen und polypeptide, die diese enthalten, zur behandlung von krankheiten und erkrankungen, die mit il-6r in zusammenhang stehen |
CA2758191C (en) | 2009-04-10 | 2015-06-30 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
ES2622366T3 (es) | 2009-10-26 | 2017-07-06 | F. Hoffmann-La Roche Ag | Procedimiento para la producción de una inmunoglobulina glucosilada |
EP2504030A4 (de) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | Il-6-antagonisten zur erhöhung von albumin und/oder senkung von crp |
US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
HRP20221490T1 (hr) | 2010-05-28 | 2023-02-03 | Chugai Seiyaku Kabushiki Kaisha | Poboljšanje antitumorskog odgovora t stanice |
EP3351559A3 (de) | 2010-11-08 | 2018-10-31 | F. Hoffmann-La Roche AG | Subkutan verabreichter anti-il-6-rezeptorantikörper |
DK2643018T3 (da) | 2010-11-23 | 2021-01-18 | Vitaeris Inc | Anti-il-6-antistoffer til behandling af oral mucositis |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
RU2674996C2 (ru) | 2013-07-04 | 2018-12-14 | Ф. Хоффманн-Ля Рош Аг | Иммуноферментный анализ с подавлением интерференции для определения антител к лекарствам в образцах сыворотки |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
CN107074954A (zh) | 2014-10-21 | 2017-08-18 | 埃博灵克斯股份有限公司 | Il‑6r相关疾病的治疗 |
CN107922507B (zh) | 2015-08-18 | 2022-04-05 | 瑞泽恩制药公司 | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 |
US11484591B2 (en) | 2016-02-22 | 2022-11-01 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites |
EP3596175A4 (de) | 2017-03-17 | 2021-01-13 | The Ohio State Innovation Foundation | Nanopartikel zur abgabe von chemopräventiven mitteln |
US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
KR20200074160A (ko) | 2017-10-20 | 2020-06-24 | 가꼬우호우징 효고 이카다이가쿠 | 항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물 |
JP7065589B2 (ja) | 2017-10-31 | 2022-05-12 | 株式会社明治 | IL-1β血清濃度低下用発酵乳、CXCL1血清濃度低下用発酵乳、癌に伴うIL-1βの過度な血清濃度上昇の抑制用発酵乳、または、癌に伴うCXCL1の過度な血清濃度上昇の抑制用発酵乳 |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04187645A (ja) * | 1990-11-22 | 1992-07-06 | Chuzo Kishimoto | インターロイキン―6作用抑制剤 |
US5795965A (en) * | 1991-04-25 | 1998-08-18 | Chugai Seiyaku Kabushiki Kaisha | Reshaped human to human interleukin-6 receptor |
IL101692A0 (en) | 1991-05-03 | 1992-12-30 | Amgen Inc | Recombinant b oligomer of pertussis toxin |
FR2694767B1 (fr) * | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
CA2146988A1 (en) * | 1992-10-13 | 1994-04-28 | Gideon Strassmann | Treatment of cachexia and inhibition of il-6 activity |
-
1996
- 1996-02-13 WO PCT/JP1996/000310 patent/WO1996025174A1/ja active IP Right Grant
- 1996-02-13 DK DK96901998T patent/DK0811384T3/da active
- 1996-02-13 JP JP52482896A patent/JP4540132B2/ja not_active Expired - Fee Related
- 1996-02-13 ES ES96901998T patent/ES2264135T3/es not_active Expired - Lifetime
- 1996-02-13 AT AT96901998T patent/ATE330629T1/de active
- 1996-02-13 EP EP96901998A patent/EP0811384B1/de not_active Expired - Lifetime
- 1996-02-13 DE DE69636278T patent/DE69636278T2/de not_active Expired - Lifetime
- 1996-02-13 AU AU46342/96A patent/AU693318B2/en not_active Ceased
- 1996-02-13 CA CA2211578A patent/CA2211578C/en not_active Expired - Fee Related
- 1996-02-13 PT PT96901998T patent/PT811384E/pt unknown
- 1996-02-13 US US08/875,927 patent/US6261560B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2211578C (en) | 2010-09-21 |
PT811384E (pt) | 2006-11-30 |
ATE330629T1 (de) | 2006-07-15 |
WO1996025174A1 (fr) | 1996-08-22 |
DK0811384T3 (da) | 2006-10-09 |
ES2264135T3 (es) | 2006-12-16 |
DE69636278T2 (de) | 2007-05-03 |
US6261560B1 (en) | 2001-07-17 |
AU4634296A (en) | 1996-09-04 |
CA2211578A1 (en) | 1996-08-22 |
EP0811384B1 (de) | 2006-06-21 |
EP0811384A1 (de) | 1997-12-10 |
EP0811384A4 (de) | 2002-09-18 |
AU693318B2 (en) | 1998-06-25 |
JP4540132B2 (ja) | 2010-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69636278D1 (de) | Inhibitor des muskelproteinabbaus enthaltend einen il-6 rezeptor antikörper | |
NZ513699A (en) | Recombinant IL-18 antagonists useful in treatment of IL-18 mediated disorders | |
IL103981A0 (en) | Pharmaceutical compositions for treatment of multiple sclerosis | |
HUP0402653A2 (hu) | Interleukin 15-re (IL-15-re) specifikus emberi antitestek | |
DE69839992D1 (de) | Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff | |
DE69634900D1 (de) | Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis | |
DK1265928T3 (da) | RSV-neutraliserende antistoffer med ultra høj affinitet | |
WO1997017446A3 (en) | HUMANIZED ANTIBODIES TO HUMAN gp39, COMPOSITIONS CONTAINING AND THERAPEUTIC USE THEREOF | |
ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
DE69939316D1 (de) | Antikörper gegen il6 zur vorbeugung und behandlung entzündlicher darmerkrankungen | |
PH12012501089A1 (en) | Therapeutic human anti-il-1r1 monoclonal antibody | |
HK1096859A1 (en) | Methods for treating interleukin-6 related diseases | |
PT735818E (pt) | Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y | |
DK1347730T4 (da) | Rekombinante anti-CD30-antistoffer og anvendelser deraf | |
ATE305779T1 (de) | Behandlung cytokin-vermittelter krankheiten mit tec familie protein tyrosin kinase inhibitoren | |
RU94045826A (ru) | Моноклональные антитела против рецептора интерферона, с нейтрализующим действием против интерферона типа i | |
GEP20063774B (en) | Blocking Monoclonal Antibody to VLA-1 and Its Use for Treatment of Inflammatory Disorders | |
DE69626522T2 (de) | Peptide mit pronociceptiveigenschaften | |
DE3855801D1 (de) | Anwendungsgebiete von beta-adrenergenen Agonisten | |
NZ337601A (en) | Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics by inhibiting IgE expression | |
WO2001072334A3 (en) | Methods for treating disease with antibodies to cxcr3 | |
Wallach et al. | Presence of tumor necrosis factor and lymphotoxin in clinical interferon preparations derived from leukocytes | |
CA2079230A1 (en) | Bcrf1 antagonists for treating epstein-barr virus infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |